HF
NMRA icon

HRT Financial’s Neumora Therapeutics NMRA Stock Holding History

HRT Financial’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-198,851
Closed -$387K – 4985
2026
Q1 		$387K Buy
+198,851
New +$515K ﹤0.01% 2706
2025
Q3 		– Sell
-45,064
Closed -$33K – 3411
2025
Q2 		$33K Buy
+45,064
New +$34.1K ﹤0.01% 2355

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's NMRA Position: Q2 2026 in Review

HRT Financial sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 198,851 shares — an estimated $387K sold.

HRT Financial first reported a position in NMRA in Q2 2025 and held it in 2 quarters. The position peaked at $387K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • HRT Financial reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 198,851 Neumora Therapeutics shares in Q2 2026, an estimated $387K.
  • HRT Financial first reported a position in Neumora Therapeutics in Q2 2025 and held it in 2 quarters.
  • HRT Financial's Neumora Therapeutics position peaked at $387K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.